
Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation
Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the European Commission (EC) granted marketing authorization in the European Union (EU) for a citrate-free high concentration formulation (HCF; 100 mg/mL) of its biosimilar Hyrimoz® (adalimumab). The approval…












